Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C.

Matsumura H, Nirei K, Nakamura H, Arakawa Y, Higuchi T, Hayashi J, Yamagami H, Matsuoka S, Ogawa M, Nakajima N, Tanaka N, Moriyama M.

J Clin Biochem Nutr. 2012 Nov;51(3):178-84. doi: 10.3164/jcbn.12-11. Epub 2012 Aug 10.

2.

Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis.

Matsuoka S, Matsumura H, Nakamura H, Oshiro S, Arakawa Y, Hayashi J, Sekine N, Nirei K, Yamagami H, Ogawa M, Nakajima N, Amaki S, Tanaka N, Moriyama M.

J Clin Biochem Nutr. 2009 Nov;45(3):292-303. doi: 10.3164/jcbn.08-246. Epub 2009 Oct 28.

3.

Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease.

Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, Yachida M, Masaki T, Kurokochi K, Watanabe S, Senda S, Kuriyama S.

Scand J Gastroenterol. 2007 Sep;42(9):1078-87.

PMID:
17710674
4.

Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.

Moriyama M, Matsumura H, Aoki H, Shimizu T, Nakai K, Saito T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.

Intervirology. 2003;46(5):296-307.

PMID:
14555850
5.

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.

Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9.

6.

A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.

Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro R, Sata M.

Dig Dis Sci. 2006 Apr;51(4):808-12.

PMID:
16615008
7.

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H.

Am J Gastroenterol. 2012 Feb;107(2):253-61. doi: 10.1038/ajg.2011.327. Epub 2011 Oct 18.

PMID:
22008893
8.
9.

High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.

Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, Shibuya A, Adachi S, Miura Y, Fujiyama S, Miyase S, Tomita K.

Scand J Gastroenterol. 2009;44(11):1340-8. doi: 10.3109/00365520903222681.

PMID:
19891585
11.

Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.

Murakami Y, Koyabu T, Kawashima A, Kakibuchi N, Kawakami T, Takaguchi K, Kita K, Okita M.

J Nutr Sci Vitaminol (Tokyo). 2007 Jun;53(3):213-8.

12.

Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Indian children.

Bhandari N, Bahl R, Taneja S, Strand T, Mølbak K, Ulvik RJ, Sommerfelt H, Bhan MK.

Pediatrics. 2002 Jun;109(6):e86.

PMID:
12042580
13.

Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases.

Yamagamim H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T, Kaneko M, Shioda A, Tanaka N, Arakawa Y.

Cancer. 2002 Aug 15;95(4):824-34.

14.
15.

Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease.

Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y.

Dig Dis Sci. 2006 Nov;51(11):1967-77. Epub 2006 Oct 18.

PMID:
17048113
16.

Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis.

Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K.

Exp Ther Med. 2012 Dec;4(6):972-976. Epub 2012 Sep 17.

17.

The long term efficacy of glycyrrhizin in chronic hepatitis C patients.

Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H.

Cancer. 1997 Apr 15;79(8):1494-500.

PMID:
9118029
18.
19.
20.

Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.

Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.

Liver Int. 2005 Feb;25(1):85-90.

PMID:
15698403
Items per page

Supplemental Content

Write to the Help Desk